Condensed Consolidated Balance Sheets - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 3,211,930	$ 5,478,113
Research and development tax incentive receivable	287,597	433,852
Prepaid assets and other current assets	1,362,989	1,678,353
Total current assets	4,862,516	7,590,318
Operating lease right-of-use asset, net	99,431	119,529
Property and equipment, net	1,879,696	1,999,781
Note receivable - Augmenta	2,337,219	2,310,000
Other assets	7,688	7,688
Total assets	9,186,550	12,027,316
Current liabilities:
Accounts payable	1,663,544	958,442
Accrued liabilities	1,983,426	1,285,586
Deferred research grant revenue	140,000	101,000
Current portion of operating lease liability	84,300	83,512
Total current liabilities	3,871,270	2,428,540
Operating lease liability, net of current portion	10,856	31,742
Total liabilities	3,882,126	2,460,282
Commitments and contingencies (see Note 5)
Stockholders’ equity:
Common stock; $0.001 par value, 180,000,000 shares authorized; 2,519,220 and 2,370,000 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively	2,519	2,370
Additional paid-in capital	129,572,489	128,044,509
Accumulated other comprehensive loss	(203,787)	(148,192)
Accumulated deficit	(124,066,797)	(118,331,653)
Total stockholders’ equity	5,304,424	9,567,034
Total liabilities and stockholders’ equity	$ 9,186,550	$ 12,027,316